AR104863A1 - Derivados imidazol - Google Patents
Derivados imidazolInfo
- Publication number
- AR104863A1 AR104863A1 ARP160101615A ARP160101615A AR104863A1 AR 104863 A1 AR104863 A1 AR 104863A1 AR P160101615 A ARP160101615 A AR P160101615A AR P160101615 A ARP160101615 A AR P160101615A AR 104863 A1 AR104863 A1 AR 104863A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- cyclopropyl
- ch2oh
- ethyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) en la que: R¹ es CH₃, R¹ es metilo, etilo, CF₃, ciclopropilo, CH₂OH o R¹ y R¹ pueden formar conjuntamente con el átomo de carbono al que se encuentran unidos un anillo 1,1-dioxo-tiolán-3-ilo, R² es hidrógeno, metilo, etilo, isopropilo, terc-butilo, ciclopropilo, CH₂OH o C(CH₃)₂OH, R³ es Cl, F, CF₃, ciano, metilo o ciclopropilo, R⁴ es hidrógeno, metilo o F, o a una sal o sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero y/o isómero óptico y/o estereoisómero correspondiente de los mismos, para la utilización en el tratamiento de trastornos psiquiátricos tales como la esquizofrenia, el trastorno bipolar, el trastorno obsesivo-compulsivo o trastornos del espectro autista.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15170671 | 2015-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104863A1 true AR104863A1 (es) | 2017-08-23 |
Family
ID=53284112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101615A AR104863A1 (es) | 2015-06-04 | 2016-06-02 | Derivados imidazol |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10029989B2 (es) |
| EP (1) | EP3303299B1 (es) |
| JP (1) | JP6877359B2 (es) |
| CN (1) | CN107531642B (es) |
| AR (1) | AR104863A1 (es) |
| HK (1) | HK1245269A1 (es) |
| TW (1) | TW201718511A (es) |
| WO (1) | WO2016193235A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6518789B2 (ja) | 2015-04-23 | 2019-05-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 精神障害の処置において使用するためのテトラゾール誘導体 |
| JP6831376B2 (ja) | 2015-10-06 | 2021-02-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | トリアゾール誘導体 |
| WO2017133990A1 (en) | 2016-02-02 | 2017-08-10 | F. Hoffmann-La Roche Ag | Pyrazol-pyridine derivatives as eaat3 inhibitors |
| CN109071451B (zh) * | 2016-05-27 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 作为eaat3抑制剂的吡唑化合物 |
| WO2018069362A1 (en) | 2016-10-14 | 2018-04-19 | F. Hoffmann-La Roche Ag | Imidazole compounds as eaat3 inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007042545A1 (en) * | 2005-10-14 | 2007-04-19 | Neurosearch A/S | Imidazole derivatives and their use for modulating the gaba-a receptor complex |
| CN103159692B (zh) * | 2006-06-29 | 2015-03-18 | 弗·哈夫曼-拉罗切有限公司 | 四唑取代的芳基酰胺类 |
| WO2009058298A1 (en) * | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3, receptor antagonists for treatment of pain |
| CA2708791C (en) * | 2007-12-17 | 2016-06-21 | F. Hoffmann-La Roche Ag | Imidazole-substituted arylamides and uses thereof as p2x receptor antagonists |
| JP6518789B2 (ja) * | 2015-04-23 | 2019-05-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 精神障害の処置において使用するためのテトラゾール誘導体 |
-
2016
- 2016-05-31 JP JP2017555639A patent/JP6877359B2/ja active Active
- 2016-05-31 EP EP16726087.6A patent/EP3303299B1/en not_active Not-in-force
- 2016-05-31 CN CN201680022475.8A patent/CN107531642B/zh not_active Expired - Fee Related
- 2016-05-31 WO PCT/EP2016/062204 patent/WO2016193235A1/en unknown
- 2016-06-02 AR ARP160101615A patent/AR104863A1/es unknown
- 2016-06-03 TW TW105117674A patent/TW201718511A/zh unknown
-
2017
- 2017-12-04 US US15/830,399 patent/US10029989B2/en active Active
-
2018
- 2018-04-11 HK HK18104744.1A patent/HK1245269A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US10029989B2 (en) | 2018-07-24 |
| JP2018516873A (ja) | 2018-06-28 |
| HK1245269A1 (zh) | 2018-08-24 |
| TW201718511A (zh) | 2017-06-01 |
| CN107531642B (zh) | 2021-06-22 |
| EP3303299A1 (en) | 2018-04-11 |
| WO2016193235A1 (en) | 2016-12-08 |
| US20180118692A1 (en) | 2018-05-03 |
| EP3303299B1 (en) | 2019-04-24 |
| JP6877359B2 (ja) | 2021-05-26 |
| CN107531642A (zh) | 2018-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000036A1 (es) | Derivados etinilo | |
| AR104331A1 (es) | Derivados de tetrazol | |
| CR20170237A (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
| AR104863A1 (es) | Derivados imidazol | |
| DOP2017000149A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| CO2019000932A2 (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica. | |
| AR099047A1 (es) | Derivados etinilo | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| GT201300207A (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR097721A1 (es) | Derivados de etinilo | |
| AR093042A1 (es) | Derivados de etinilo | |
| AR105327A1 (es) | Derivados de imidazol | |
| AR107490A1 (es) | Derivados de pirazol-piridina como inhibidores de eaat3 | |
| CO2018013824A2 (es) | Derivados de etinilo | |
| AR106475A1 (es) | Derivados de piridina o de pirimidina | |
| BR112016017816A8 (pt) | derivados de etinila, seus usos, e composição farmacêutica | |
| AR103952A1 (es) | Derivados de pirimidina-diona | |
| EA201692404A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| CR20150143A (es) | Derivados de etinilo como moduladores del receptor de actividad mglur5 | |
| AR099300A1 (es) | Hexahidrofuropirroles como inhibidores de pde1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |